* A Symbicort
sales decline of 8% (3% at CER) to $585m.
M2 PHARMA-May 22, 2019-New trial data reveals effectiveness of AstraZeneca's Symbicort
M2 EQUITYBITES-May 22, 2019-New trial data reveals effectiveness of AstraZeneca's Symbicort
LONDON (Alliance News) - AstraZeneca PLC's Novel Start trial for its Symbicort
Turbuhaler demonstrated a reduction in the rate of asthma attacks in patients with mild asthma compared to common therapies.
Recently, scientific evidence shows that the most effective controller medicines are those that contain formoterol such as Symbicort
Geographies covered: US Germany France Italy Spain UK Japan Australia Canada Drugs covered Spiriva Tudorza Pressair Seebri Neohaler Incruse Ellipta Arcapta Neohaler/Onbrez Striverdi Respimat Advair/Seretide Symbicort
Turbuhaler Breo Ellipta Ultibro/Utibron Anoro Ellipta Brimica Genuair/Duaklir Stiolto Respimat Daliresp/Daxas Trelegy Ellipta Trimbow Arnuity Ellipta Bevespi Aerosphere Lonhala Magnair Revefenacin PT010 Nucala RPL554 Fasenra Disease Indication Overview: This section of the report gives the overview of COPD disease indication in detail.
AstraZeneca announced results from the Phase III SYGMA trials of Symbicort
Turbuhaler (budesonide/formoterol) given as an anti-inflammatory reliever as needed versus two different treatment regimens in patients with mild asthma.
The products that will no longer carry this boxed warning in their labels include AstraZeneca's budesonide/formoterol fumarate dihydrate (Symbicort
) and GlaxoSmithKline's fluticasone furoate/vilanterol (Breo Ellipta) and fluticasone propionate/salmeterol (Advair Diskus and Advair HFA).
AstraZeneca PLC has been cleared by the Food and Drug Administration to update the label for Symbicort
inhalation aerosol (budesonide/formoterol fumarate dihydrate), including removal of the boxed warning for serious asthmarelated outcomes.
sales were down 28% to $3.0 billion, due to the loss of exclusivity for Crestor and Seroquel XR as well as the impact of Symbicort
sales, which declined by 19% to $554 million.
KG); Spiromax (IVAX International B.V.); Swinghaler (Otsuka Pharamceutical Co., Ltd); Symbicort
and Turbuhaler (AstraZeneca AB); Twisthaler (MSD International Holdings GmbH).
* Seretide (fluticasone propionate/salmeterol; GSK): Seretide and Symbicort
have nearly equal numbers of Promoters.